Jonathan E. Brammer

Oct 12, 2024 | tandfonline.com | Jonathan E. Brammer |Alice Mims |Sarah Wall |Jean Caputo

FDA approved agents for the treatment of chronic GVHD including ruxolitinib and belumosudil are effective steroid-sparing agents, with overall response rates (ORR) of 76% and 65% respectively. Ruxolitinib and belumosudil are well tolerated with different primary targets. Little data is available on the use of combination ruxolitinib and belumosudil.